

Treatment Naïve and Treatment Experienced

# Ledipasvir + Sofosbuvir +/- Ribavirin in GT 1-3 ELECTRON 2


Source: Gane EJ, et al. 49<sup>th</sup> EASL. 2014: Abstract O6.

# Sofosbuvir-Ledipasvir +/- Ribavirin in GT 1 & 3 ELECTRON 2 Trial: Features

## ELECTRON 2 Trial

- **Design:** Open-label, phase 2, using fixed-dose combination of ledipasvir-sofosbuvir +/- ribavirin in treatment-naïve and treatment-experienced genotype 1 and in treatment-naïve genotype 3
- **Setting:** Hepatitis treatment centers in New Zealand
- **Entry Criteria**
  - Chronic HCV (n=90)
  - Group 1: GT1, prior failure with sofosbuvir-based regimen (all relapse)
  - Group 2: GT1, decompensated cirrhosis (Child-Turcotte-Pugh class B)
  - Group 3: GT3, treatment naïve
- **Primary End-Point:** SVR12

# Sofosbuvir-Ledipasvir +/- Ribavirin in GT 1 & 3 ELECTRON 2: Study Design



**Abbreviations:** LDV-SOF = ledipasvir-sofosbuvir; RBV = ribavirin

## Drug Dosing

Ledipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once daily


Ribavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg

# Sofosbuvir-Ledipasvir +/- Ribavirin in GT 1 & 3 ELECTRON-2: Baseline Characteristics

	GT 1 Prior SOF	GT 1 CPT Class B	GT 3 Treatment Naïve	
	LDV-SOF + RBV n=19	LDV-SOF n=20	LDV-SOF n=25	LDV-SOF + RBV n=26
Mean age, years	55	56	43	48
Male, n (%)	13 (68)	17 (85)	13 (52)	11 (42)
White, n (%)	18 (95)	17 (85)	22 (88)	23 (88)
Mean BMI, kg/m <sup>2</sup>	27	31	27	28
Cirrhosis, n (%)	0	20 (100)	3 (12)	5 (19)
IL28B CC, n (%)	4 (21)	7 (35)	9 (36)	15 (58)
GT 1a, n (%)	17 (89)	18 (90)	0	0
GT 1b, n (%)	2 (11)	2 (10)	0	0
GT 3a, n (%)	0	0	25 (100)	26 (100)
Mean HCV RNA, log <sub>10</sub> IU/mL	6.3	6.0	6.3	6.3

# Sofosbuvir-Ledipasvir +/- Ribavirin in GT 1 & 3 ELECTRON 2: Study Design

## SVR 12, by GT and Treatment Regimen



LDV-SOF = ledipasvir-sofosbuvir; RBV = ribavirin

Source: Gane EJ, et al. 49<sup>th</sup> EASL. 2014: Abstract O6.

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.